Cases & Deals

  • Home
  • Practices
  • Junshi grants exclusive rights to Dr. Reddy's for toripalimab cancer treatment

Share

Junshi grants exclusive rights to Dr. Reddy's for toripalimab cancer treatment

May 2023

Client(s) Shanghai Junshi Biosciences Co., Ltd.

Jones Day represented Shanghai Junshi Biosciences Co., Ltd. ("Junshi") in its grant of exclusive rights related to the development and commercialization of toripalimab, an anti-PD1 monoclonal antibody, to Dr. Reddy's Laboratories for the territory of Latin America, India, South Africa, and an option to expand the territory to include Australia and New Zealand and potential other countries. Junshi also granted rights of first negotiation with respect to two additional products for the same geographical regions. Toripalimab is in various states of clinical trials throughout the world evaluating the safety and efficacy for the treatment of cancer tumors of the lungs, esophagus, stomach, bladder, breast, liver, kidney, and skin, and has been approved in China and marketed under the TUOYI® trademark.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.